|
|
|
|
Undiagnosed Celiac Disease Associated With Nearly Quadrupled Mortality
Celiac disease, an immune system reaction to gluten in the diet, is over four times more common today than it was 50 years ago, according to findings of a Mayo Clinic study published this month in the journal Gastroenterology.The study...
|
|
|
Anemia increases PE mortality risk
MedWire News: Pulmonary embolism (PE) patients with low levels of hemoglobin (Hb) have a greater risk of dying than their counterparts without anemia, research suggests.David Jimnez Castro (Ramn y Cajal Hospital, Madrid, Spain) and...
|
|
|
FDA approves new IV iron therapy for CKD
The drug is not yet approved for an oncology setting.Print Email Discuss in our forum The FDA has approved ferumoxytol injection for intravenous use as an iron replacement therapy for the treatment of iron deficiency anemia in adult...
|
|
|
Undiagnosed Celiac Disease Associated With Nearly Quadrupled Mortality
Celiac disease, an immune system reaction to gluten in the diet, is over four times more common today than it was 50 years ago, according to findings of a Mayo Clinic study published this month in the journal Gastroenterology.The study...
|
|
|
Preoperative hemoglobin level as a predictor of survival after coronary artery bypass grafting. A comparison w
Study of how the preoperative hemoglobin level affects pt survival after CABG Comparison of late mortality for CABG pts vs general population Determination of early and late mortality of all consecutive pts undergoing isolated CABG January...
|
|
|
FDA Approves Feraheme' To Treat Iron Deficiency Anemia In Adult Chronic Kidney Disease Patients
AMAG Pharmaceuticals, Inc.(NASDAQ:AMAG) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Feraheme" (ferumoxytol) Injection for intravenous (IV) use as an iron replacement therapy for the...
|
|
|
FDA Approves Feraheme To Treat Iron Deficiency Anemia In Adult Chronic Kidney Disease Patients
AMAG Pharmaceuticals, Inc.(NASDAQ:AMAG) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Feraheme (ferumoxytol) Injection for intravenous (IV) use as an iron replacement therapy for the...
|
|
|
FDA Approves Feraheme to Treat Iron Deficiency Anemia in Adult Chronic Kidney Disease Patients
- AMAG Pharmaceuticals, Inc.(NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Feraheme (ferumoxytol) Injection for intravenous (IV) use as an iron replacement therapy for...
|
|
|
FDA Approves Feraheme? to Treat Iron Deficiency Anemia in Adult Chronic Kidney Disease Patients
LEXINGTON, Mass.--(BUSINESS WIRE)-- AMAG Pharmaceuticals, Inc.(NASDAQ:AMAG) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Feraheme? (ferumoxytol) Injection for intravenous (IV) use...
|
|
|
Amag Pharmaceuticals wins FDA approval for anemia drug
(Datamonitor via COMTEX) -- Amag Pharmaceuticals, a biopharmaceutical company, has received marketing approval from the FDA for Feraheme injection for intravenous use as an iron replacement therapy for the treatment of iron deficiency ...
|
|
|
FDA Gives OK To Anemia Drug
(New York, NY) -- The maker of the injectable anemia medicine Feraheme says the Food and Drug Administration has given its approval to the drug.AMAG Pharmaceuticals says Feraheme will be available to patients by the second half of...
|
|
|
Ferumoxytol Approved to Treat Iron Deficiency Anemia in Chronic Kidney Disease
_ Ferumoxytol Approved to Treat Iron Deficiency Anemia in Chronic Kidney Disease.
|
|
|
Ferumoxytol Approved to Treat Iron Deficiency Anemia in Chronic Kidney Disease
_ Ferumoxytol Approved to Treat Iron Deficiency Anemia in Chronic Kidney Disease.
|
|
|
Ferumoxytol Approved to Treat Iron Deficiency Anemia in Chronic Kidney Disease
_ Ferumoxytol Approved to Treat Iron Deficiency Anemia in Chronic Kidney Disease.
|
|
|
AMAG Anemia Drug Wins US Approval, Shares Jump
AMAG Pharmaceuticals Inc said U.S.AMAG Anemia Drug Wins US Approval, Shares Jump.
|
|
|
BioWorld Today July 1, 2009
It was a day late - but AMAG Pharmaceuticals Inc.will hardly end up any dollars short. Aftermarket word Tuesday that the FDA approved AMAG's Feraheme as an iron replacement therapy sent relief through some quarters, though...
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and M
ity Research highlights AMAG Pharmaceuticals Inc.(Nasdaq: AMAG | Quote | Chart | News | PowerRating) as the Bull of the Day and Palm, Inc. (Nasdaq: PALM | Quote | Chart | News | PowerRating) the Bear of the Day. In addition, Zacks...
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and M
http://www.profit.zacks.com/ CHICAGO--(Business Wire)-- Zacks Equity Research highlights AMAG Pharmaceuticals Inc.(Nasdaq: AMAG) as the Bull of the Day and Palm, Inc. (Nasdaq:PALM) the Bear of the Day. In addition, Zacks Equity...
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re,
BusinessWire - Zacks Equity Research highlights AMAG Pharmaceuticals Inc.(Nasdaq: AMAG) as the Bull of the Day and Palm, Inc. (Nasdaq: PALM) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Everest Re (NYSE...
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals
highlights AMAG Pharmaceuticals Inc.(Nasdaq: AMAG) as the and Palm, Inc. (Nasdaq:PALM) the. In addition, provides analysis on Everest Re (NYSE:RE), Ace Limited (NYSE:ACE) and Montpelier (NYSE:MRH). Full analysis of all these stocks...
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and M
CHICAGO--(BUSINESS WIRE)-- highlights AMAG Pharmaceuticals Inc.(Nasdaq: AMAG) as the and Palm, Inc. (Nasdaq: PALM) the. In addition, provides analysis on Everest Re (NYSE: RE), Ace Limited (NYSE: ACE) and Montpelier (NYSE: MRH).
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and M
CHICAGO--(BUSINESS WIRE)-- highlights AMAG Pharmaceuticals Inc.(Nasdaq: AMAG) as the and Palm, Inc. (Nasdaq: PALM) the. In addition, provides analysis on Everest Re (NYSE: RE), Ace Limited (NYSE: ACE) and Montpelier (NYSE: MRH).
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and M
CHICAGO--(BUSINESS WIRE)-- highlights AMAG Pharmaceuticals Inc.(Nasdaq: AMAG) as the and Palm, Inc. (Nasdaq: PALM) the. In addition, provides analysis on Everest Re (NYSE: RE), Ace Limited (NYSE: ACE) and Montpelier (NYSE: MRH).
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and M
Zacks Equity Research highlights AMAG Pharmaceuticals Inc.( NASDAQ:AMAG) as the Bull of the Day and Palm, Inc. ( NASDAQ:PALM) the Bear of the Day. In addition, Zacks Equity Research provides analysis on Everest Re ( NYSE:RE), Ace...
|
|
|
Zacks Bull and Bear of the Day Highlights: AMAG Pharmaceuticals Inc., Palm, Inc. Everest Re, Ace Limited and M
Zacks Bull and Highlights: AMAG Pharmaceuticals Inc., Palm, Inc.Everest Re, Ace Limited and Montpelier http://www.profit.zacks.com/ CHICAGO--(BUSINESS WIRE)-- highlights AMAG Pharmaceuticals Inc. (Nasdaq: AMAG) as the and Palm, Inc. ...
|
